Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of...
Bellicum Pharma (BLCM) Halted, News Pending
Generally, stocks with a low price-to-earnings (P/E) ratio are favored by investors. The perception is that the lower the P/E, the higher will be the value of the stock. This...
Aratana Therapeutics, Inc. (NASDAQ:PETX) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more...
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for...
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. The Company has developed CAR-T product candidates in cellular immunotherapy through which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors (CARs). It uses a Chemical Induction of Dimerization (CID) technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. Its product candidates include BPX-601 and BPX-603. BPX-601, is an autologous GoCAR-T product candidate containing inducible MyD88/CD40 (iMC) activation switch, designed to treat solid tumors expressing prostate stem cell antigen (PSCA). BPX-603 is its dual-switch GoCAR-T product candidate and is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.
|Moving Averages||Sell||Sell||Sell||Sell||Strong Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Buy||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Neutral||Strong Sell||Strong Sell|